Endocrinologists and endocrinology HCPs interested in the treatment and management of obesity.

Upon completion of this activity, the learner will be able to:
• Describe the biological mechanisms of appetite and weight control that are dysregulated in people with obesity
• Discuss the link between obesity and its comorbidities, including cardiometabolic diseases
• Evaluate the latest clinical data for available/emerging anti-obesity medications indicated in adults and adolescents
• Identify appropriate treatment plans for individuals with obesity and comorbid conditions

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and The Institute for Medical and Nursing Education (IMNE). The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Domenica Rubino, MD - Program Chair
Washington Center for Weight Management & Research
Arlington, VA

Sean Wharton, MD, FRCPC, PharmD
Wharton Medical Clinic 
Toronto, Ontario, Canada 

Michael Vallis, PhD. R. Psych 
Psychologist and Associate Professor
Dalhousie University – Halifax, NS, Canada 

Judith Korner, MD, PhD
Columbia University
New York, NY

Jaime Paul Almandoz, MD, MBA, FTOS
UT Southwestern Medical Center
Dallas, TX

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

• Domenica Rubino, MD: Epitomee Medical, Astra Zeneca; Boehringer Ingelheim, Novo Nordisk - Investigator (Institutional); Novo Nordisk, Boehringer Ingelheim, Eli Lilly - Consultant; Novo Nordisk – Speaker and Writing Support; Boehringer Ingelheim – Advisor; Prime Therapeutics, Medscape/WebMD, PeerView, Endocrine Society, ADA - Honoraria

• Sean Wharton, MD, FRCPC, PharmD: BI, Lilly, Novo Nordisk, Bausch Health Canada - Speakers bureau; BioHaven, BI - Consultant; BI, Lilly, Novo Norkisk, Bausch Health Canada - Contracted Research
  
  
• Michael Vallis, PhD. R. Psych: Abbvie, Abbott, Bausch Health, Boehringer Ingelheim, Llifescan, Lyceum, Novo Nordisk, Roche, Sanofi – Ad Boards and Consultations; Abbott, Abbvie, Bausch Health, Lifescan, Lilly, Merck, Novo Nordisk, Pfizer, Roche, Sanofi – Speakers Fees; Abbott, Bausch Health, Novo Nordisk – Research Funding

• Judith Korner. MD, PhD: GI Dynamics, Gila Therapeutics, Found Health – Advisory Board; American Board of Obesity Medicine – Board; Digma Medical – Consultant; Servier Laboratories – Expert Witness; UptoDate – Reviewer
  
  
• Jaime Paul Almandoz, MD, MBA, FTOS: Novo Nordisk, Eli Lilly – Advisory Board; Boehringer Ingelheim – Consulting.

The following faculty reported no relevant financial relationships:

The following committee member who planned and reviewed content for this activity reported the following financial relationship: 

• Tareneh Soleymani, MD
  Penn University
  Hummelstown, PA
  NovoNordisk - Speaker

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgment of Commercial Support: This educational activity is supported by an educational grant from Novo Nordisk.